Search review questions

Presence of PHN 6 months after the onset of acute herpetic rashClinical manifestation · people with acute herpes zoster (within 7 days of onset of rash)

Serious adverse eventsClinical manifestation and laboratory examination · people with acute herpes zoster (within 7 days of onset of rash)

Non‐serious adverse eventsClinical manifestation and laboratory examination · people with acute herpes zoster (within 7 days of onset of rash)

CTS symptoms (Boston CTS questionnaire) ‐ short‐term improvement: < 3 monthsScale: 1 to 5, higher is worse · carpal tunnel syndrome

CTS symptoms (Boston CTS questionnaire) ‐ long‐term improvement: > 3 monthsScale: 1 to 5, higher is worse · carpal tunnel syndrome

Function (Boston CTS questionnaire) ‐ long‐term improvement: > 3 monthsScale: 1 to 5, higher is worse · carpal tunnel syndrome

Overall improvement (improved/not improved or worsened) ‐ short‐term improvement: < 3 months · carpal tunnel syndrome

Health‐related quality of life ‐ long‐term improvement: > 3 months · carpal tunnel syndrome

Adverse effects · carpal tunnel syndrome

Referral for surgery · carpal tunnel syndrome

Improvement in symptoms at ≤ 3 months · people with carpal tunnel syndrome

Improvement in function at ≤ 3 months · people with carpal tunnel syndrome

Improvement in symptoms at > 3 months · people with carpal tunnel syndrome

Improvement in neurophysiological parameters at ≤ 3 months · people with carpal tunnel syndrome

Requirement for carpal tunnel surgery · people with carpal tunnel syndrome

Improvement in quality of life · people with carpal tunnel syndrome

Adverse events · people with carpal tunnel syndrome

Induction · people with multifocal motor neuropathy

Induction · people with multifocal motor neuropathy

Maintenance · people with multifocal motor neuropathy

Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal · people with multifocal motor neuropathy

Change in mean muscle strength in participants on IVIg treatment at study entry · people with multifocal motor neuropathy

Adverse events · people with multifocal motor neuropathy

Proportion of participants with side effects attributable to treatment · people with multifocal motor neuropathy

Proportion of participants with an improvement in disability scale used in the original study · people with multifocal motor neuropathy

Proportion of participants with an improvement of muscle strength · people with multifocal motor neuropathy

Proportion of participants with an improvement in disability at 12 months or later · people with multifocal motor neuropathy

Proportion of participants in which at least 1 conduction block resolved after therapy · people with multifocal motor neuropathy

Maintenance · people with multifocal motor neuropathy

Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal, as determined and defined by study authors · people with multifocal motor neuropathy

Proportion of IVIg‐treated participants with a decrease in muscle strength during controlled IVIg withdrawal · people with multifocal motor neuropathy

Proportion of participants with side effects attributable to treatment · people with multifocal motor neuropathy

Participant‐reported improvement in sialorrhea in the short term number of participants reporting improvement · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

Reduction in the amount of saliva production in the short term using an objective measure · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

Quality of life · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

Adverse events · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

Participant‐reported improvement in sialorrhea in the short term Various measures: two 100 mm VAS, for severity and difficulty, anchors unstated, and response based on the ALSFRS‐R (no change or better vs worse) · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via…

Reduction in the amount of saliva production in the short term using an objective measure Mean volume of daily oral suction · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via…

Quality of life · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via…

Adverse events · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via…

Reduction in the amount of saliva production in the short term using an objective measure: volume of saliva mL in 5 min (final values) · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

Quality of life: SEIQOL‐DW (0 to 100; with higher scores indicating better quality of life) (final values) · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

Adverse effects · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

Participant‐reported improvement in sialorrhea in the short term, measured using the Drool Rating Scale (DRS) (range 8 to 39; higher scores indicate worse drooling) · people with motor neuron disease/amyotrophic lateral sclerosis with excessive saliva

Reduction in the amount of saliva production in the short term using an objective measure · people with motor neuron disease/amyotrophic lateral sclerosis with excessive saliva

Quality of life · people with motor neuron disease/amyotrophic lateral sclerosis with excessive saliva

Adverse events, reported as "negative experiences" · people with motor neuron disease/amyotrophic lateral sclerosis with excessive saliva

Participant‐reported improvement in sialorrhea in the short term · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

Muscle strength at ≥ 24 months · people undergoing peripheral nerve repair of the upper limb

Sensory recovery at ≥ 24 months · people undergoing peripheral nerve repair of the upper limb